CJC-1295 (No DAC), also known as modified GRF (1–29) without drug affinity complex, is a synthetic analog of growth hormone–releasing hormone (GHRH). It is widely studied in endocrinology and molecular biology research for its role in activating GHRH receptors in the anterior pituitary, leading to stimulation of endogenous growth hormone secretion.
In laboratory and preclinical research settings, CJC-1295 (No DAC) is examined for its effects on growth hormone pulsatility, hypothalamic–pituitary axis signaling, and downstream pathways involving insulin-like growth factor-1 (IGF-1). Unlike DAC-modified versions, the No DAC variant is studied for its shorter duration of receptor engagement, allowing researchers to investigate more physiologic patterns of growth hormone release.
Research involving CJC-1295 (No DAC) focuses on endocrine signaling dynamics, receptor-mediated activity, and growth hormone regulation mechanisms rather than therapeutic or clinical application.
